Trial · NCT03439072
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Subjects With a Positive Glucose Response | 0 to 30 minutes post dose | Intent to treat analysis population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time for Positive Glucose Response | 0 to 180 minutes post dose | Intent-to treat analysis population | minutes | MEAN |
| SECONDARY | Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Positive Glucose Increase | 0 to 30 minutes post dose | Intent to treat analysis population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With a Positive Glucose Increase | 0 to 30 minutes post dose | Intent to treat analysis population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time for Positive Glucose Increase | 0 to 180 minutes post dose | Intent to treat analysis population | minutes | MEAN |
| SECONDARY | Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Relief of Neuroglycopenic Symptoms | 0 to 30 minutes post dose | Intent to treat analysis population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With Relief of Neuroglycopenic Symptoms | 0 to 30 minutes post dose | Intent to treat analysis population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time to Resolution of Autonomic Symptoms | 0 to 180 minutes post dose | Intent to treat analysis population | minutes | MEAN |
| SECONDARY | Time to Resolution of Neuroglycopenic Symptoms | 0 to 180 minutes post dose | Intent to treat analysis population | minutes | MEAN |
| SECONDARY | Time to Resolution of the Feeling of Hypoglycemia | 0 to 180 minutes post dose | Intent to treat analysis population | minutes | MEAN |
| SECONDARY | Glucose AUC | 0 to 180 minutes post dose - Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose. | Intent to treat analysis population. Due to missing data AUC was only evaluable in 67 subjects per arm. | mg∙min/dL | MEAN |
| SECONDARY | Glucose Cmax | 0 to 180 minutes post dose - Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose. | Intent to treat analysis population | mg/dL | MEAN |
| SECONDARY | Glucose Tmax | 0 to 180 minutes post dose | Intent to treat analysis population | minutes | MEAN |
| SECONDARY | Glucagon Preparation and Administration Time | 0 to 5 minutes pre-dose | Intent to treat analysis population | seconds | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03439072/outcomes